Abstract
Aim:Cystic echinococcosis (CE) has potential economic effects to both animal products and human health. A vaccine to protect livestock against CE can be effective in reducing economic costs and increasing the livestock products. Protoscolex tegumental surface antigens (PSTSA) used to induce the production of specific antibodies against Echinococcus granulosus in sheep. The tegumental antigens were extracted from viable protoscolices by solubilization in sterile phosphate-buffered saline containing decanoyl-N-methylglucamine.Materials and Methods:Ten lambs which were infected with CE (positive control), 10 negative control, and 10 test groups of sheep were included in the study. 300 µg emulsion of purified-PSTSA was injected intramuscularly in a two-step immunization on the first and 30 days. Sera were collected immediately before immunization and 6 times with 10-day intervals until 60 days post immunization. Thereafter, the sera were tested for antibodies by indirect hemagglutination test in microtiter plate.Results:After two immunizations, all the infected animals in test group showed substantial increases in antibody titer. Statistical analysis showed a significant difference between the titer obtained in the test and negative control groups in both phases of immunization (p<0.05).Conclusion:The results showed that the PSTSA is a promising immunogenic compound for immunization of sheep against CE.
Highlights
Echinococcus granulosus is a small cyclophyllidean tapeworm (3-5 mm long) with an indirect life cycle
Materials and Methods: Ten lambs which were infected with Cystic echinococcosis (CE), 10 negative control, and 10 test groups of sheep were included in the study. 300 μg emulsion of purified-Protoscolex tegumental surface antigens (PSTSA) was injected intramuscularly in a two-step immunization on the first and 30 days
The results showed that the PSTSA is a promising immunogenic compound for immunization of sheep against CE
Summary
Echinococcus granulosus is a small cyclophyllidean tapeworm (3-5 mm long) with an indirect life cycle. It is estimated that human burden of disease is 1,009,662 (95% confidence interval [CI] 862,119-1,175,654) disability-associated life
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
